In the latest episode of the Beyond Journal Club podcast from Core IM and NEJM Group, the hosts unpack the evolving language of steatotic liver disease and discuss two major trials: MAESTRO-NASH studying resmetirom, the first FDA-approved liver-directed therapy for MASH, and ESSENCE, evaluating semaglutide in biopsy-confirmed disease
Clare J Lee, Huzhang Mao, Vivian T Thieu, Laura Fernndez Land, Melissa K Thomas Journal of the Endocrine Society , Volume 7, Issue 5, May 2023, bvad056 Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes (T2D)
Do not stop Rybelsus without medical advice
This allows the nutrient to be delivered directly to the cells that need it most, mimicking the body's natural way of transporting molecules